Concurrent Use of Tiotropium (Spiriva) and Inhaled Mometasone in Asthma and COPD

1. Evidence of Benefit in Asthma

Tiotropium received U.S. FDA approval in 2015 for patients ≥ 12 years with asthma as a once‑daily 5 µg add‑on to inhaled corticosteroid (ICS) therapy, with or without other maintenance medications【1】【2】.
In randomized trials of moderate‑to‑severe asthma uncontrolled on ICS alone, the combination of tiotropium + ICS produced lung‑function gains that were non‑inferior to the LABA salmeterol and superior to placebo【1】【2】.
Across severe‑asthma populations, adding tiotropium to ICS increased forced expiratory volume in 1 second (FEV₁) and reduced the rate of exacerbations【1】【2】.
The reduction in asthma exacerbations with the tiotropium + ICS regimen occurred regardless of whether patients had a high or low type‑2 eosinophilic phenotype【2】【3】.

Triple therapy (tiotropium + ICS + long‑acting β‑agonist) improved lung function and health‑related quality of life to a degree that met minimally important clinical thresholds in COPD patients【4】.
Adding the fixed‑dose combination fluticasone‑salmeterol to tiotropium therapy further enhanced lung function, quality of life, and lowered hospitalization rates in moderate‑to‑severe COPD【5】【6】.

Tiotropium: 5 µg once daily via Respimat inhaler (2 puffs of 2.5 µg each)【1】【2】.
Mometasone: Standard asthma‑severity dosing, typically a medium‑to‑high dose when used together with tiotropium【1】【2】.

Tiotropium: 18 µg once daily via HandiHaler device【7】【5】【8】.
Mometasone: Delivered as part of an ICS/LABA combination product (e.g., fluticasone‑salmeterol)【9】.

The most frequent adverse effect of tiotropium was dry mouth, reported in approximately 10 % of participants【10】.
Serious adverse events did not differ between tiotropium + ICS combination therapy and monotherapy arms in large trials【10】.
Safety and tolerability over 48‑week study periods were consistent across adult age groups【1】【2】.

In COPD, inhaled corticosteroids are linked to a higher risk of pneumonia (relative risk ≈ 1.55), especially in patients with severe disease【10】.
This pneumonia risk must be weighed against documented benefits of improved lung function, better health status, and fewer exacerbations when ICS are combined with tiotropium【9】.

Step 1 – Persistent symptoms on ICS alone: Add tiotropium 5 µg daily for asthma or 18 µg daily for COPD【1】【2】【8】.
Step 2 – Persistent symptoms on ICS + LABA: Introduce tiotropium as part of triple therapy (tiotropium + ICS + LABA)【4】【6】.

All statements are supported by the cited peer‑reviewed evidence.